News | April 11, 2025
US court lifts launch restrictions on Sun Pharma's autoimmune drug
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
USFDA inspection at Alembic Pharma's Bioequivalence facility
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Subscribe To Our Newsletter & Stay Updated
